Safety of baricitinib for the treatment of atopic dermatitis over a median of 1.6 years and up to 3.9 years of treatment: an updated integrated analysis of eight clinical trials.
Saved in:
| Title: | Safety of baricitinib for the treatment of atopic dermatitis over a median of 1.6 years and up to 3.9 years of treatment: an updated integrated analysis of eight clinical trials. |
|---|---|
| Authors: | Bieber, Thomas1,2 (AUTHOR) thomas.bieber@ukbonn.de, Katoh, Norito3 (AUTHOR), Simpson, Eric L.4 (AUTHOR), de Bruin-Weller, Marjolein5 (AUTHOR), Thaçi, Diamant6 (AUTHOR), Torrelo, Antonio7 (AUTHOR), Sontag, Angelina8 (AUTHOR), Grond, Susanne8 (AUTHOR), Issa, Maher8 (AUTHOR), Lu, Xiaoyu9 (AUTHOR), Cardillo, Tracy8 (AUTHOR), Holzwarth, Katrin8 (AUTHOR), Thyssen, Jacob P.10 (AUTHOR) |
| Source: | Journal of Dermatological Treatment. 2023, Vol. 34 Issue 1, p1-10. 10p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
